score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.6505	372.0	1.6e-05	0.0		Putatively Actionable	Dabrafenib + Trametinib	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Tafinlar [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2018.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/202806s008lbl.pdf	Putatively Actionable	Panitumumab	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0.0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	0	92.0	0.6739	1.0	BRAF p.V600E (Missense)	1.0	MEL-IPI_Pat15	MEL-IPI_Pat15-Tumor-SM-4DK1B	MEL-IPI_Pat15-Normal-SM-4NFUH
Investigate Actionability - High	Clinical evidence			Somatic Variant	ERBB3	Missense	p.D1129H	0.3106	132.0	0.0	0.0		Investigate Actionability - High	Neratinib	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475												0	402.0	0.2612	1.0	ERBB3 p.D1129H (Missense)		MEL-IPI_Pat15	MEL-IPI_Pat15-Tumor-SM-4DK1B	MEL-IPI_Pat15-Normal-SM-4NFUH
Investigate Actionability - High			Inferential	Aneuploidy	Whole genome doubling																				Investigate Actionability - High	0.0	WGD was associated with adverse survival pan-cancer in patients with advanced disease and in cancers with heterogeneous clinical outcomes, even following the development of metastasis.	Bielski CM, Zehir A, Penson AV, et al. Genome doubling shapes the evolution and prognosis of advanced cancers Nat Genet. 2018; 50(8):1189-1195.	https://doi.org/10.1038/s41588-018-0165-1	0						MEL-IPI_Pat15		
Investigate Actionability - Low		Preclinical		Somatic Variant	NFE2L2	Missense	p.L107F	0.2576	198.0	0.0	0.0								Investigate Actionability - Low	Radiation therapy	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616						0	0.0	0.0	0.0	NFE2L2 p.L107F (Missense)		MEL-IPI_Pat15	MEL-IPI_Pat15-Tumor-SM-4DK1B	MEL-IPI_Pat15-Normal-SM-4NFUH
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.E238K	0.3317	419.0	1.6e-05	0.0																			0	0.0	0.0	0.0	RUNX1T1 p.E238K (Missense)		MEL-IPI_Pat15	MEL-IPI_Pat15-Tumor-SM-4DK1B	MEL-IPI_Pat15-Normal-SM-4NFUH
Biologically Relevant				Somatic Variant	CDKN2A	Splice Site		0.9286	14.0	0.0	0.0																			0	81.0	1.0	1.0	CDKN2A  (Splice Site)		MEL-IPI_Pat15	MEL-IPI_Pat15-Tumor-SM-4DK1B	MEL-IPI_Pat15-Normal-SM-4NFUH
Biologically Relevant				Microsatellite Stability	Supporting variants		PRDM2 p.703_704insP (Insertion), MSH3 p.AAAAAA52del (Deletion), MSH3 p.PPA66del (Deletion)																							0				Supporting variants: PRDM2 p.703_704insP (Insertion), MSH3 p.AAAAAA52del (Deletion), MSH3 p.PPA66del (Deletion)		MEL-IPI_Pat15		
Biologically Relevant				Mutational Signature	COSMIC Signature 7		0.57																							0				COSMIC Signature 7 (57%)		MEL-IPI_Pat15		
